TCGA-OR-A5JM-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.607
- G2M_CHECKPOINT+0.564
- CHOLESTEROL_HOMEOSTASIS+0.476
- MITOTIC_SPINDLE+0.385
- PANCREAS_BETA_CELLS+0.363
- SPERMATOGENESIS+0.347
- MYC_TARGETS_V1+0.324
- MTORC1_SIGNALING+0.291
- PROTEIN_SECRETION+0.277
- ANDROGEN_RESPONSE+0.222
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.453
- INTERFERON_GAMMA_RESPONSE-0.355
- INTERFERON_ALPHA_RESPONSE-0.306
- OXIDATIVE_PHOSPHORYLATION-0.288
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.285
- IL6_JAK_STAT3_SIGNALING-0.278
- HEDGEHOG_SIGNALING-0.248
- WNT_BETA_CATENIN_SIGNALING-0.233
- INFLAMMATORY_RESPONSE-0.220
- IL2_STAT5_SIGNALING-0.188
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278878 | — | — | 0.830 |
| 2 | TCGA-OR-A5K9-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.768 |
| 3 | TCGA-44-7670-01A-11R-2066-07 | — | cohortA4 | 0.764 |
| 4 | TCGA-OR-A5LE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.763 |
| 5 | SRR25617890 | — | B | 0.755 |
| 6 | SRR33532819 | — | E | 0.755 |
| 7 | TCGA-E2-A14V-01A-11R-A12D-07 | — | C | 0.750 |
| 8 | ERR2598208 | fetal | fetal | 0.744 |
| 9 | 53fd72a0-30b5-4488-afb2-e77c2fd6a0d4 | — | — | 0.744 |
| 10 | R397 | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.607 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.564 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.476 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.385 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.363 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.347 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.324 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.291 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.277 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.222 | Inavolisib | — uncovered |
| PEROXISOME | 0.191 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.178 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.153 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.147 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.126 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.109 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.106 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.102 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.076 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.051 | Inavolisib | — uncovered |